Delving into the Latest Updates on Genting Pharmaceutical (Suzhou Co Ltd. with Synapse

Overview

Tags

Neoplasms

Infectious Diseases

Digestive System Disorders

Small molecule drug

Antibody drug conjugate (ADC)

mRNA vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Hemic and Lymphatic Diseases	3
Immune System Diseases	3
Infectious Diseases	3
Nervous System Diseases	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	4
mRNA vaccine	2
Antibody drug conjugate (ADC)	1
Therapeutic vaccine	1
Prophylactic vaccine	1

Top 5 Target	Count

BTK(Tyrosine-protein kinase BTK)	1
S1PR1 x S1PR4 x S1PR5	1
30S subunit(30S ribosomal subunit)	1
FGFR4(Fibroblast growth factor receptor 4)	1
Top I x Trop-2	1

主要目的：评估Sacituzumab Govitecan相较于医生选择的治疗（TPC）用于治疗转移性或者局部晚期不可切除的尿路上皮癌（UC）患者的总生存期（OS）。次要目的：1. 评估并比较sacituzumab govitecan与TPC治疗的无进展生存期（PFS），基于研究者和盲态独立中心审查（BICR）根据RECIST1.1标准的评估。2. 评估并比较sacituzumab govitecan与TPC治疗的客观缓解率（ORR）、临床获益率（CBR）和客观肿瘤缓解持续时间（DOR），基于研究者和BICR根据RECIST1.1标准的评估。3. 评估并比较sacituzumab govitecan和TPC治疗的安全性和耐受性。4. 评估并比较sacituzumab govitecan和TPC治疗的生活质量（QOL）。

[Translation]

Primary Objective: To evaluate the overall survival (OS) of sacituzumab govitecan compared with treatment of physician's choice (TPC) for the treatment of patients with metastatic or locally advanced unresectable urothelial carcinoma (UC). Secondary Objectives: 1. To evaluate and compare the progression-free survival (PFS) of sacituzumab govitecan and TPC treatment, based on the evaluation of the investigator and blinded independent central review (BICR) according to RECIST1.1 criteria. 2. To evaluate and compare the objective response rate (ORR), clinical benefit rate (CBR), and objective duration of tumor response (DOR) of sacituzumab govitecan and TPC treatment, based on the evaluation of the investigator and BICR according to RECIST1.1 criteria. 3. To evaluate and compare the safety and tolerability of sacituzumab govitecan and TPC treatment. 4. To evaluate and compare the quality of life (QOL) of sacituzumab govitecan and TPC treatment.

Start Date11 Aug 2021

Sponsor / Collaborator

Everest Medicines II HK Ltd.

[+2]

100 Clinical Results associated with Genting Pharmaceutical (Suzhou Co Ltd.

Login to view more data

0 Patents (Medical) associated with Genting Pharmaceutical (Suzhou Co Ltd.

Login to view more data

100 Deals associated with Genting Pharmaceutical (Suzhou Co Ltd.

Login to view more data

100 Translational Medicine associated with Genting Pharmaceutical (Suzhou Co Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

Phase 2

Phase 3

1

NDA/BLA

Approved

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Eravacycline Dihydrochloride ( 30S subunit )	Complicated intra-abdominal infection More	Approved
Etrasimod Arginine ( S1PR1 x S1PR4 x S1PR5 )	Colitis, Ulcerative More	Phase 3
Civorebrutinib ( BTK )	Kidney Diseases More	Phase 2
Roblitinib ( FGFR4 )	Hepatocellular Carcinoma More	Phase 1/2
mRNA Cancer Vaccine(Everest Medicines)	Solid tumor More	Preclinical